" class="no-js "lang="en-US"> Fairtility Launches AI Academy to Demystify Use of Artificial Intelligence in Fertility Care - Medtech Alert
Wednesday, April 10, 2024

Fairtility Launches AI Academy to Demystify Use of Artificial Intelligence in Fertility Care

Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the launch of the AI Academy, a new educational platform that will host healthcare and technology experts to engage the IVF community in the conversation around the responsible adoption of AI innovation in IVF care.

Fairtility launched the AI Academy at the European Society of Human Reproduction and Embryology (ESHRE) 38th Annual Meeting, which took place in Milan, ItalyJuly 3-6. Dr. Gerard Letterie, a leader in reproductive endocrinology and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.

Dr. Letterie introduced the first AI Academy session, which was followed by a panel discussion with four of the world’s recognized authorities in the field of IVF, including:

  • Weill Cornell Medical College’s Dr. Nikica Zaninovic, Associate Professor of Embryology in Clinical Obstetrics and Gynecology
  • IVIRMA’s Dr. Marcos Meseguer, Scientific Supervisor and Senior Embryologist at the IVI Valencia IVF unit
  • Dr. Cristina Hickman, Clinical Embryology Consultant and VP Clinical Affairs for Fairtility
  • Hadassah Hebrew University Medical Center’s Dr. Assaf Ben Meir, Director of Fertility and IVF Unit, and co-founder and chief medical officer of Fairtility.

“At ESHRE, we confirmed our understanding of the state of AI in IVF: the field is evolving and maturing rapidly and the uptake of these tools hinges on education and understanding. The industry knows that AI presents an important opportunity in fertility care, but does not fully understand what capabilities and limitations exist, nor what to expect out of AI in this field,” commented Dr. Letterie. “Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care. IVF professionals will develop a deeper understanding of this technology and how it can serve them in their work, and ultimately, improve IVF outcomes for prospective parents. I am honored to head the AI Academy with the support of Fairtility, hosting the finest minds from diverse fields including embryology, AI, digital health, clinical research and more.”

“We believe that knowledge is the best tool to resolve concerns of the unknown and help usher in the capabilities of AI to advance the efficacy of IVF treatment. We are investing in education for IVF professionals to better understand the potential for AI to transform the IVF industry,” said Eran Eshed, CEO and Co-Founder of Fairtility. “We are building a community of experts and creating a space for dialogue, the sharing of ideas, innovation and productive argumentation – all in an effort to advance our industry to its fullest potential.”

The AI Academy will host an impressive roster of speakers covering a range of topics from the basics of AI, AI and the IVF lab, AI in clinical and management, as well as ethics and best practices in AI’s application. The first AI Academy session, entitled, “AI, the new frontier: Everything you need to know about this tech” will take place on September 2, 2022, and will be led by Dr. Nadav Rapoport of Ben Gurion University’s Department of Software and Information Systems Engineering.

“We see expanding interest as AI technology for IVF continues to advance, yet there are no definable parameters or baselines for AI’s adoption in this industry. Our AI Academy is poised to center the pendulum on AI by establishing a coherent, organized field that provides accessible education and conversation, bringing early and late adopters together to shorten the innovation adoption cycle for AI in fertility care,” added Eshed.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more